Clinical Observation of Botulinum Toxin A Treatment in the Treatment of Rosacea

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Feb 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of Botox (also known as botulinum toxin) to see how effective and safe it is for treating rosacea, a skin condition that causes redness and visible blood vessels on the face. The researchers want to find out if Botox can help reduce the symptoms of mild to moderate rosacea in participants aged 18 and older.

To join the study, participants need to have a confirmed diagnosis of mild to moderate rosacea and be able to commit to following the treatment plan for 12 weeks. However, people who have had facial cosmetic surgery or Botox treatments in the last six months, have certain health conditions, or are pregnant or breastfeeding cannot participate. Those who join can expect to receive the treatment and have their progress monitored throughout the study. This is an opportunity to potentially benefit from a new approach to managing rosacea while contributing to important research.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Meeting the diagnostic criteria of mild to moderate erythema telangiectasis rosette acne;
• • more than 18 years old;
• • to obey the rules of the treatment in the study, and can be followed up for 12 weeks;
• • informed consent;
• Exclusion Criteria:
• • Had received facial cosmetic surgery or botulinum toxin treatment within 6 months before this treatment;
• • due to systemic diseases such as autoimmune diseases or menopause facial flush;
• • had allergies botulinum toxin;
• • pregnant or breastfeeding;
• • other facial skin or oral disease therapy, including research before 4 weeks rose acne accept other treatment;
• • With basic neuromuscular diseases (such as myasthenia gravis, amyotrophic lateral sclerosis, etc.);
• • All landowners 4 weeks before the study whether any oral aminoglycoside drugs, benzodiazepines drugs or muscle relaxants; .Was removed during treatment observation data is not complete, incomplete treatment and patients can't take medication as prescribed.